Effects of Xingnaojing combined with edaravone on neurological function and serum HMGB-1,TGF-β1 and ICAM-1 levels in patients with acute cerebral hemorrhage
Objective To investigate the effects of Xingnaojing combined with edaravone on neurological function and serum high mobility group box-1 protein(HMGB-1),transforming growth factor-β1(TGF-β1)and intercellular adhesion molecule-1(ICAM-1)levels in patients with acute cerebral hemorrhage.Methods A total of 128 patients with acute cerebral hemorrhage admitted from 2018 to 2022 were selected as the research objects and divided into study group and control group according to the random number table method,with 64 cases in each group.The control group was treated with edaravone,and the study group was treated with Xingnaojing combined with edaravone.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the hematoma volume,absolute edema volume,relative hematoma volume,the National Institutes of Health Stroke Scale(NIHSS)score,HMGB-1,TGF-β1,ICAM-1,tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)levels in the two groups decreased,the Glasgow Coma Scale(GCS)score increased,and those in the study group were better than the control group(P<0.05).Conclusion Xingnaojing combined with edaravone can significantly reduce the volume of brain hematoma in patients with acute cerebral hemorrhage,reduce inflammation,promote the recovery of neurological function,and improve clinical efficacy.
万方数据
